Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) announces a strategic collaboration with Xcell Biosciences, Inc. to enhance the development of cell and gene therapies (CGTs). This partnership aims to improve the safety and efficacy of CGTs and will involve projects utilizing Xcellbio’s AVATAR incubator system. The collaboration aligns with Labcorp’s commitment to advancing CGT capabilities and supporting pharmaceutical companies in accelerating therapeutic development. Labcorp, with over 20 years of experience, has been instrumental in supporting the development of FDA-approved CAR-T cell and gene therapies.
Labcorp (NYSE: LH) has declared a cash dividend of $0.72 per share, payable on June 9, 2022, to stockholders of record by May 19, 2022. This marks the initiation of quarterly dividends as part of their financial strategy. Future dividends will depend on the company's financial health, operational results, and Board discretion. Labcorp reported a revenue of $16 billion in FY2021, signaling robust performance in the life sciences sector.
Ventus Therapeutics has appointed Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences, bringing over 25 years of experience in computational methods for drug discovery. Dr. Lobanov will lead the company's computational efforts and enhance the ReSOLVE platform while integrating machine learning and structural biology. His past roles include significant contributions at Johnson & Johnson (NYSE: JNJ) and Labcorp Drug Development (NYSE: LH). Ventus aims to leverage his expertise to optimize drug discovery processes, focusing on challenging protein targets.
Labcorp (NYSE: LH) will announce its first quarter 2022 financial results on April 28, 2022, before market opens. A conference call will follow at 9 a.m. EDT to discuss these results. Interested parties can access the call by dialing the designated numbers or joining the webcast on the Labcorp Investor Relations website. An audio replay will be available until May 12, 2022. In FY2021, Labcorp reported revenue of $16 billion, showcasing its position as a leader in the life sciences sector.
Labcorp, a leading global life sciences company, is the first commercial laboratory in the U.S. to offer quantitative testing for gluten in stool samples. This innovative test, developed in collaboration with Immundiagnostik, Inc., allows individuals to accurately assess unintentional gluten consumption. With increasing awareness of celiac disease and non-celiac gluten sensitivity (NCGS), the demand for reliable testing is rising. The new test aims to provide healthcare providers and patients with critical information to better manage gluten exposure and dietary choices.
Labcorp (NYSE: LH) has announced a strategic partnership with Prisma Health, South Carolina's largest health system, to enhance laboratory services for patients and physicians. The collaboration involves Labcorp acquiring certain assets from Prisma's outreach lab business and providing technical support to improve hospital laboratory operations. This initiative aims to expand access to laboratory testing across South Carolina, including same-day STAT testing, and is anticipated to close in the second half of 2022, although specific transaction terms remain undisclosed.
Walgreens and Labcorp have launched the nationwide availability of the Pixel by Labcorp® COVID-19 at-home collection kit, accessible at no cost to eligible individuals via Labcorp OnDemand™. This initiative, in partnership with the U.S. Department of Health and Human Services, aims to enhance testing accessibility for underserved communities. Walgreens President John Standley emphasized the importance of reducing healthcare barriers, particularly for uninsured populations. The program complements Walgreens' existing free drive-thru testing at over 7,000 locations and contributes to broader healthcare efforts amidst evolving COVID-19 conditions.
Labcorp (NYSE: LH) has successfully completed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics. This strategic acquisition enhances Labcorp's liquid biopsy capabilities and expands its oncology portfolio, specifically its next-generation sequencing (NGS)-based genomic profiling products. The deal aims to improve patient outcomes in oncology. The definitive agreement was initially announced on December 23, 2021, highlighting Labcorp's commitment to advancing its diagnostics and drug development capabilities.
Labcorp (NYSE: LH) announced its 2021 Q4 and full-year results, reporting revenues of $4.06 billion for Q4, down 9.7% year-over-year, and $16.12 billion for the full year, a 15.3% increase. Diluted EPS fell to $5.75 in Q4 from $9.54 a year prior, while full-year adjusted EPS rose to $28.52 from $23.94. The company expects a robust outlook for 2022, targeting adjusted EPS between $17.25 and $21.25 and free cash flow of $1.7 to $1.9 billion. Labcorp's oncology position will strengthen with the acquisition of Personal Genome Diagnostics and a key partnership with Ascension.
Labcorp (NYSE: LH) has announced a strategic collaboration with Ascension, enhancing access to lab services across 10 states in the U.S. Labcorp will manage Ascension’s hospital labs and acquire select outreach lab assets. This partnership aims to improve patient care by leveraging Labcorp's expertise in areas like oncology and neurology. The transactions, pending regulatory approval, are expected to close in the first half of 2022, marking a significant step in Labcorp's mission to innovate healthcare.